Given that sorafenib-treated HCC cells develop resistance by activating the cholesterol pathway via the FAK/AKT axis—and that cotreatment with sorafenib and defactinib can effectively overcome this resistance—we sought to construct a cholesterol pathway–based gene signature to predict sorafenib resistance. This evidence concerns the gene PTK2 and hepatocellular carcinoma.